Abstract 10036: Apolipoproteins and Cardiovascular-Kidney-Metabolic-Biomarkers Each Add to Prediction of Residual Cardiovascular Disease Risk After Acute Coronary Syndrome: Insights from the ODYSSEY OUTCOMES Trial
The conclusion that residual risk in ACS is multidimensional is supported, and comprehensive biomarker profiling with a multiplex apolipoprotein panel including apoE phenotypes and emerging CKM tests each provides clinically meaningful improvement in the prediction of MACE and death beyond conventional demographics, di...